Compare CORT & ESE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | ESE |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.1B |
| IPO Year | 2001 | 1994 |
| Metric | CORT | ESE |
|---|---|---|
| Price | $111.91 | $295.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $96.50 | ★ $283.33 |
| AVG Volume (30 Days) | ★ 1.3M | 174.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.10% |
| EPS Growth | N/A | ★ 193.15 |
| EPS | 0.09 | ★ 3.71 |
| Revenue | ★ $761,407,000.00 | $37,000,000.00 |
| Revenue This Year | $26.08 | $21.42 |
| Revenue Next Year | $26.98 | $6.99 |
| P/E Ratio | $1,267.14 | ★ $123.20 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $182.85 |
| 52 Week High | $122.21 | $362.15 |
| Indicator | CORT | ESE |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 38.63 |
| Support Level | $76.41 | $290.64 |
| Resistance Level | $122.21 | $309.57 |
| Average True Range (ATR) | 5.21 | 11.75 |
| MACD | 0.55 | -2.06 |
| Stochastic Oscillator | 72.40 | 14.58 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.